Bingyang Shi obtained his Ph.D. from the University of Adelaide, Australia. Since 2014, he has led the Brain Drug Delivery Group at Macquarie University, Australia, where his research addresses one of the major challenges for brain disease therapy which is the successful delivery of therapeutic agents across the blood–brain barrier. The research covers three core research streams: 1) development of novel nanoparticle-based blood–brain barrier (BBB) penetration mechanisms; 2) development of brain delivery systems based on the BBB mechanisms discovered in stream 1; 3) preclinical evaluation of therapies for brain diseases based on the delivery systems developed in stream 2.
Webpage
